Gilead Sciences Q4 Sales Rise 5% to $7.92B, FY26 EPS Guidance Tops Forecast
Gilead posted Q4 sales of $7.92 billion, a 5% increase that topped the $7.57 billion consensus and sparked a 6% stock surge. Full-year EPS jumped 76% to $8.15 and the company guided FY26 EPS of $8.45–$8.85, beating the $8.61 estimate despite slightly softer sales forecasts.
1. Q4 Performance
Gilead reported fourth-quarter revenue of $7.92 billion, up 5% year over year and above the $7.57 billion consensus. HIV franchise sales increased 6% on strong demand for Biktarvy and Descovy, while liver disease revenue climbed 17% led by Livtildzi, with adjusted EPS of $1.86 beating forecasts.
2. Full-Year Results and Guidance
For fiscal 2025, Gilead delivered EPS of $8.15, a 76% gain from $4.62, on $29.44 billion in sales. The company forecasts FY26 revenue of $29.6–$30 billion, slightly below the $30.04 billion consensus, but expects EPS of $8.45–$8.85, exceeding the $8.61 street estimate.
3. Valuation and Investor Metrics
Gilead trades at 17x forward earnings, below the industry average of 19x, while offering a 2.15% dividend yield versus the S&P 500’s 1.07%. The company’s return on invested capital stands at 24%, underlining robust capital efficiency compared with peers.